$AQST News

Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027

Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Aquestive Therapeutics: Potential Catalyst On The Horizon

Aquestive (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Aquestive Therapeutics, Inc. Q2 2026 Earnings Call Summary

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates